Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy.
Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy.
复制标题
DOI：
10.3390/v14102153
复制
发表时间：
2022-09-29
期刊：
影响因子：
--
通讯作者：
Ryo A
中科院分区：
文献类型：
--
作者：
Hatayama Y;Yamaoka Y;Morita T;Jeremiah SS;Miyakawa K;Nishi M;Kimura Y;Mitsunaga M;Iwase T;Kimura H;Yamamoto N;Takaori-Kondo A;Hasegawa H;Ryo A
人类 T 细胞白血病病毒 1 型 (HTLV-1) 是一种逆转录病毒，可引起成人 T 细胞白血病淋巴瘤、HTLV-1 相关脊髓病/热带痉挛性截瘫和 HTLV-1 葡萄膜炎。目前，尚无针对 HTLV-1 感染的抗逆转录病毒疗法或疫苗。本研究旨在开发一种针对 HTLV-1 包膜蛋白 (Env) 的抗体，并将其应用于近红外光免疫抗菌策略 (NIR-PIAS)，以消除 HTLV-1 感染的细胞。我们通过脂质体和重组蛋白的复合物进行免疫，建立了针对 HTLV-1 Env 的小鼠单克隆抗体 (mAb)。详细的表位作图表明，其中一种单克隆抗体与 gp46 富含脯氨酸的区域结合，并且没有表现出明显的抑制病毒感染的中和活性。相反，mAb 很少内化到细胞内，并保留在 HTLV-1 感染细胞的细胞表面上。与光敏染料 IRDye700Dx 结合的抗体可识别 HTLV-1 感染的细胞，并在近红外辐射后杀死它们。这些结果表明，新型 mAb 和 NIR-PIAS 可以开发为针对 HTLV-1 感染细胞的新靶向治疗工具。
Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus, causes adult T-cell leukemia-lymphoma, HTLV-1 associated myelopathy/tropical spastic paraparesis, and HTLV-1 uveitis. Currently, no antiretroviral therapies or vaccines are available for HTLV-1 infection. This study aimed to develop an antibody against the HTLV-1 envelope protein (Env) and apply it to a near-infrared photoimmuno-antimicrobial strategy (NIR-PIAS) to eliminate HTLV-1 infected cells. We established mouse monoclonal antibodies (mAbs) against HTLV-1 Env by immunization with a complex of liposome and the recombinant protein. Detailed epitope mapping revealed that one of the mAbs bound to the proline-rich region of gp46 and exhibited no obvious neutralizing activity to inhibit viral infection. Instead, the mAb was rarely internalized intracellularly and remained on the cell surface of HTLV-1-infected cells. The antibody conjugated to the photosensitive dye IRDye700Dx recognized HTLV-1 infected cells and killed them following NIR irradiation. These results suggest that the novel mAb and NIR-PIAS could be developed as a new targeted therapeutic tool against HTLV-1 infected cells.
登录
查看更多内容
影响因子：
64.8
作者：
Jumper J;Evans R;Pritzel A;Green T;Figurnov M;Ronneberger O;Tunyasuvunakool K;Bates R;Žídek A;Potapenko A;Bridgland A;Meyer C;Kohl SAA;Ballard AJ;Cowie A;Romera-Paredes B;Nikolov S;Jain R;Adler J;Back T;Petersen S;Reiman D;Clancy E;Zielinski M;Steinegger M;Pacholska M;Berghammer T;Bodenstein S;Silver D;Vinyals O;Senior AW;Kavukcuoglu K;Kohli P;Hassabis D
通讯作者：
Hassabis D
影响因子：
12.4
作者：
Jing H;Weidensteiner C;Reichardt W;Gaedicke S;Zhu X;Grosu AL;Kobayashi H;Niedermann G
通讯作者：
Niedermann G
影响因子：
5.4
作者：
Lavillette, D;Maurice, M;Cosset, FL
通讯作者：
Cosset, FL
影响因子：
11.2
作者：
Koya J;Saito Y;Kameda T;Kogure Y;Yuasa M;Nagasaki J;McClure MB;Shingaki S;Tabata M;Tahira Y;Akizuki K;Kamiunten A;Sekine M;Shide K;Kubuki Y;Hidaka T;Kitanaka A;Nakano N;Utsunomiya A;Togashi Y;Ogawa S;Shimoda K;Kataoka K
通讯作者：
Kataoka K
无症状 HTLV-1 携带者的人类 T 细胞白血病病毒 I 型（HTLV-1）前病毒载量和疾病进展：日本的一项全国性前瞻性研究
影响因子：
20.3
作者：
Iwanaga, Masako;Watanabe, Toshiki;Yamaguchi, Kazunari
通讯作者：
Yamaguchi, Kazunari